title: An open-label, split-face trial evaluating efficacy and safty of photopneumatic therapy for the treatment of acne.
abstract: BACKGROUND
  Acne vulgaris is the most common skin disease worldwide, with many available treatment modalities, including oral and topical medications and laser therapy. Recently, a novel device (Isolaz, Pleasanton, CA, USA) that combines vacuum pressure and a broadband light source (400 nm to 1,200 nm) was developed for the treatment of acne.
  
  
  OBJECTIVE
  To determine the clinical efficacy and safety of photopneumatic therapy for the treatment of acne vulgaris of the face.
  
  
  METHODS
  Twenty adults with mild to moderate facial acne vulgaris received 4 successive treatments on one side of the face with a combined photopneumatic device (intense pulsed light: fluence=5.8 J/cm(2); negative pressure=iMP mode) at 2 week intervals. Acne lesions on the opposite side of the face were not treated. Lesion counts were performed at baseline, prior to each treatment session, and at 3 months after the final treatment session.
  
  
  RESULTS
  Significant lesion improvements and reduced numbers of acne lesions were observed on the treated side of the faces. Most patients experienced global clinical improvement. No severe side effects occurred during the study, with only a few patients experiencing transient erythema, purpura and/or exacerbation of pre-existing acne.
  
  
  CONCLUSIONS
  Photopneumatic therapy is a safe and effective treatment for mild to moderate acne vulgaris.
authors.affiliation: Department of Dermatology, Kyung Hee University School of Medicine, Seoul, Korea.
authors.forename: Eun Ju
authors.initials: EJ
authors.lastname: Lee
authors.forename: Hee Kyeong
authors.initials: HK
authors.lastname: Lim
authors.forename: Min Kyung
authors.initials: MK
authors.lastname: Shin
authors.forename: Dong-Hye
authors.initials: DH
authors.lastname: Suh
authors.forename: Sang-Jun
authors.initials: SJ
authors.lastname: Lee
authors.forename: Nack In
authors.initials: NI
authors.lastname: Kim